Advertisement
News
Advertisement

IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"

Tue, 01/22/2013 - 10:54am
Bio-Medicine.Org

NEW YORK, Jan. 22, 2013 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced that on January 17, 2013 the Company received a notice of allowance regarding its U.S. Patent Application Serial No. 13/323,030 entitled "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells." The allowed claims apply to IntelliCell's proprietary method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.

Steven Victor MD, Chairman and CEO of IntelliCell stated, "We are very excited to receive this notice of allowance from the US Patent Office.  We believe that this is a very significant milestone for the Company and for the advancement of regenerative medicine.  The fact that we can produce viable stromal vascular fraction cells, the regenerative cells of the human body, without resorting to the use of enzymes which have the potential to effect fundamental change on the cells, is a significant step forward in the potential uses of stromal vascular fraction cells for the treatment of serious disease states and conditions.  This patent and others in process will establish IntelliCell's position as a leader in the industry focused on the minimal manipulation of human tissues to be used for regenerative procedures.  We look forward to announcing additional upcoming milestones in our continuing mission to demonstrate the safety and efficacy of our cellular treatments to the scientific, me
'/>"/>

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading